Vetter Adds Flexible Serialization Service to Its Portfolio
Vetter has announced it now offers the option of clearly identifying packaging used for drugs. Vetter's comprehensive and flexible serialization service is in response to stricter guidelines from the regulatory authorities of many countries aimed at combatting counterfeit drugs. Pharma and biotech companies can use Vetter's individually customizable solutions as a basis for their own track-and-trace programs to optimize their supply chain.
The number of counterfeit drugs on the market is growing and has quickly become a serious global challenge, putting patients at considerable risk, and costing the pharmaceutical industry a significant amount of money. Lawmakers and regulatory agencies around the world have responded by creating new guidelines to increase drug safety. Government and industry both agree that the best available solution is tracking and tracing drugs from production to distribution, on through to the dispensary or the pharmacy. The key to reaching that goal is serialization and Track-and-Trace; the distinct identification of the smallest packaging unit with a unique identification number.
In some countries, scuh as Turkey, India, China, and Argentina, regulators are already calling for drugs to be serialized. Many other markets will be following suit in the coming years, including South Korea, Brazil, the US, and the EU. The requirements and specific serialization guidelines however, are country specific, which is why pharmaceutical companies operating internationally need flexible solutions to meet these differing requirements. That is why Vetter offers various options for the serialization of drugs. These include making available different serial number and code formats, interfaces and reports or various aggregation depths. And there are, of course, national differences that must be taken into account. South Korea, for example, expects that by 2015, serialization will be included on the item level, while China follows still another concept, including 1D linear codes as well as aggregation with shipping boxes.
"Our serialization service allows for unique identification of the unit level and transportation packaging," says Thomas Otto, Vetter Managing Director. Therefore, we are providing a flexible response to the stricter demands of official agencies, while at the same time actively contributing to greater drug safety. Our customers benefit additionally from the fact that they can use the new service as a basis for their own track-and-trace program. Transparency in distribution prevents counterfeits, but it also promotes greater efficiency for processes along the supply chain."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance